After hours: March 20 at 7:49:50 PM EDT Loading Chart for BEAM ...

The CBE projects goal is to provide practical data governance via a generic schema/API/persistence layer which can be used for all the common functions in an enterprise and extended for each ...

It has been around a year since Beam Therapeutics slashed its headcount and R&D programmes to focus mainly on a sickle cell disease candidate – and the biotech has now revealed the first data ...

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported ...

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns ...

Preliminary results from a small clinical trial suggest that a cutting-edge genetic medicine developed by Beam Therapeutics can repair the damaged DNA that gives rise to a rare liver and lung disorder ...

The FDA is taking a cautious approach to gene editing clinical trials in the United States, forcing companies to go overseas for early data generation.

The Central Bank of Egypt (CBE) issued a statement on Tuesday, specifying the working hours of banks during the holy month of Ramadan, the closing time of banks for the public and the end of working ...

Bank of New York Mellon Corp raised its stake in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 21.7% during the 4th quarter, HoldingsChannel.com reports.The firm owned 276,917 shares of ...

Beam Ther­a­peu­tics said its ex­per­i­men­tal gene edit­ing treat­ment helped low­er lev­els of mu­tant pro­teins and in­crease lev­els of cor­rect­ed pro­teins in … ...